MedTrace Logo

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 395

Last updated 2021-12-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Conditions

Interventions

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-30
Primary Completion
2013-02-04
Completion
2020-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730639 on ClinicalTrials.gov